```html

Jewel Skin Lichen (Lichen Planus Pigmentosus) – A Comprehensive Medical Guide

Overview

Lichen planus pigmentosus (LPP), sometimes called “Jewel Skin Lichen” because of the deep, slate‑gray to brown‑black patches that can look like dark jewels on the skin, is a chronic inflammatory skin disorder. It belongs to the broader family of lichen planus diseases, which affect skin, mucous membranes, hair, and nails. LPP is distinguished by its persistent hyperpigmentation rather than the classic itchy, violaceous papules seen in classic lichen planus.

• Who it affects: LPP most commonly occurs in people with darker skin tones—particularly individuals of South Asian, Middle Eastern, African, or Mediterranean descent. Women are diagnosed more often than men, with a female‑to‑male ratio of roughly 2–3:1.
• Age of onset: The condition usually appears in the third to fifth decade of life, but cases in teenagers and older adults have been reported.
• Prevalence: Precise global prevalence is difficult to determine because many cases are under‑reported. In a 2020 epidemiologic study from India, LPP accounted for about 7 % of all lichen planus presentations, translating to an estimated prevalence of 0.5–1 % among dermatology patients in regions with high melanin‑rich populations.<sup>1</sup>

Symptoms

LPP manifests primarily as patches of discoloration, but the presentation can vary. Below is a complete symptom list with brief descriptions:

• Hyperpigmented macules or patches – Flat, well‑defined areas of slate‑gray, brown, or black color, most often on the face (forehead, temples, cheeks), neck, upper chest, and flexural zones.
• Blaschko‑line distribution – In some patients, the patches follow the patterns of embryonic skin cell migration, creating linear or whorled arrangements.
• Post‑inflammatory hyperpigmentation (PIH) – After a mild inflammatory phase, the skin may retain a darker hue for months.
• Mild itching or burning – Usually less intense than classic lichen planus; itching may be intermittent.
• Surface texture changes – The lesions can be slightly raised, scaly, or have a fine roughness, but they are generally smooth.
• Koebner phenomenon – New lesions may develop at sites of trauma, such as scratching, shaving, or cosmetic procedures.
• Mucosal involvement (rare) – Occasionally, oral or genital mucosa can show a faint brown discoloration, but this is uncommon.
• Hair or nail changes – Unlike classic lichen planus, LPP rarely affects hair follicles or nails.

Causes and Risk Factors

The exact cause of LPP remains unknown, but research points to a multifactorial origin involving immune dysregulation, genetics, and environmental triggers.

Immunologic Factors

• Cell‑mediated immunity – Cytotoxic CD8+ T‑cells attack basal keratinocytes, leading to melanin incontinence and pigmentary changes.<sup>2</sup>
• Cytokine milieu – Increased levels of interferon‑γ, interleukin‑6, and tumor necrosis factor‑α have been detected in lesional skin.

Genetic Predisposition

• Family clustering has been reported, suggesting HLA‑DR and other immune‑related genes may confer susceptibility.

Environmental & Lifestyle Triggers

• Sun exposure – Ultraviolet (UV) radiation may precipitate lesions, especially on the face and neck.
• Topical agents – Chronic use of cosmetics, fragrances, or skin‑lightening creams containing hydroquinone or corticosteroids has been associated with LPP onset.<sup>3</sup>
• Medications – Certain drugs (e.g., antimalarials, beta‑blockers, angiotensin‑converting‑enzyme inhibitors) have been implicated, though data are limited.
• Hormonal factors – Higher incidence in women suggests a possible link to estrogen fluctuations, but definitive evidence is lacking.

Risk Populations

• Individuals with darker skin tones (Fitzpatrick skin types IV–VI).
• Women aged 30–50 years.
• People with a history of chronic sun exposure or who use depigmenting/topical agents frequently.

Diagnosis

A precise diagnosis of LPP relies on clinical evaluation, dermoscopic assessment, and, when necessary, skin biopsy.

Clinical Examination

• Visual inspection of characteristic hyperpigmented patches.
• Assessment of distribution pattern (face, neck, upper trunk, flexures).
• Review of medical, medication, and cosmetic use history.

Dermoscopy

Dermoscopy can reveal specific features such as gray‑brown homogeneous areas, perifollicular pigment rings, and absence of vascular structures, helping distinguish LPP from melasma or post‑inflammatory hyperpigmentation.<sup>4</sup>

Skin Biopsy

When the diagnosis is uncertain, a 4‑mm punch biopsy is performed. Histopathologic hallmarks include:

• Basal cell degeneration (lichenoid interface dermatitis).
• Band‑like lymphocytic infiltrate at the dermo‑epidermal junction.
• Melanin incontinence with dermal melanophages.
• Absence of eosinophils, which helps differentiate from drug‑induced eruptions.

Laboratory Tests

Routine labs are not diagnostic but may be ordered to rule out systemic disease:

• Complete blood count (CBC) and liver function tests if systemic lichen planus is suspected.
• Autoimmune screening (ANA, hepatitis C serology) when other lichenoid disorders are considered.

Treatment Options

Because LPP is chronic, the goal of therapy is to halt progression, lighten existing pigmentation, and prevent new lesions. Treatment must be individualized based on disease extent, patient skin type, and tolerance to medications.

Topical Therapies

• High‑potency corticosteroids (e.g., clobetasol propionate 0.05 %): Applied twice daily for 4–6 weeks can reduce inflammation and prevent further pigment deposition. Use caution to avoid skin atrophy.
• Topical calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 % cream): Safe for long‑term use, especially on the face, and helpful for patients who cannot tolerate steroids.<sup>5</sup>
• Depigmenting agents – Azelaic acid 20 % gel or hydroquinone 4 % (short‑term) may lighten existing macules, but they should be used under dermatologist supervision to avoid irritant or allergic reactions.

Systemic Treatments

• Oral corticosteroids – Short courses (e.g., prednisone 0.5 mg/kg for 2–4 weeks) are reserved for extensive, rapidly progressive disease.
• Antimalarials (hydroxychloroquine 200–400 mg daily) have shown benefit in some series, likely due to anti‑inflammatory properties.<sup>6</sup>
• Systemic retinoids (acitretin 25–35 mg/day) can reduce keratinocyte proliferation and hyperpigmentation, but teratogenic risk and lipid monitoring are required.
• Immunomodulators – Mycophenolate mofetil or low‑dose methotrexate are options for recalcitrant cases, though evidence is limited.

Procedural Interventions

• Laser therapy – Q‑switched Nd:YAG (1064 nm) or fractional CO₂ lasers can target melanophages and improve color. Multiple sessions are often needed, and post‑laser strict photoprotection is essential.
• Chemical peels – Superficial glycolic or trichloroacetic acid peels may aid in pigment clearance when combined with topical agents.
• Phototherapy – Narrow‑band UVB can be useful for widespread disease, but careful monitoring is needed because UV exposure may also exacerbate pigmentation.

Lifestyle & Supportive Measures

• Broad‑spectrum sunscreen (SPF 30 or higher) applied every 2 hours when outdoors.
• Avoidance of known irritants (fragranced creams, harsh soaps).
• Use of gentle, fragrance‑free moisturizers to preserve barrier function.
• Regular follow‑up with a dermatologist experienced in pigmentary disorders.

Living with Jewel Skin Lichen (Lichen Planus Pigmentosus)

While LPP can be cosmetically distressing, many patients achieve satisfactory control with a combination of treatments and self‑care strategies.

Daily Skin‑Care Routine

1. Cleanse gently – Use a non‑soap, pH‑balanced cleanser twice daily.
2. Moisturize – Apply a ceramide‑rich moisturizer within 5 minutes of cleansing to lock in moisture.
3. Sun protection – Reapply sunscreen, wear wide‑brim hats, and seek shade between 10 am–4 pm.
4. Medication adherence – Set reminders for topical applications; stock enough supply to avoid missed doses.

Psychosocial Tips

• Consider counseling or support groups if hyperpigmentation affects self‑esteem.
• Make-up with non‑comedogenic, high‑coverage products (e.g., mineral‑based foundations) can temporarily mask lesions.
• Document progress with photographs; this helps both patient and clinician assess treatment response.

Monitoring

Schedule dermatology visits every 3–6 months in stable disease, or sooner if new lesions appear or existing patches darken rapidly.

Prevention

Because the exact trigger is unknown, primary prevention focuses on minimizing known risk factors.

• Photoprotection – Daily sunscreen and protective clothing reduce UV‑induced inflammation.
• Gentle cosmetics – Choose hypoallergenic, fragrance‑free products; patch‑test new items before full use.
• Avoid chronic skin trauma – Limit aggressive exfoliation, chemical peels, or laser treatments on unaffected skin.
• Medication review – Discuss any new prescription or over‑the‑counter drug with your dermatologist to rule out lichenoid reactions.

Complications

If LPP remains uncontrolled, several complications may arise:

• Persistent hyperpigmentation – Can become permanent, leading to cosmetic concerns and potential psychosocial impact.
• Koebnerization – New lesions develop at sites of friction (e.g., shaving, rubbing), expanding disease distribution.
• Secondary infection – Rare, but intense scratching can break the skin barrier and permit bacterial colonization.
• Potential malignant transformation – While LPP itself is benign, chronic lichenoid inflammation has, in isolated reports, been linked to squamous cell carcinoma in classic lichen planus. Vigilance is advised for any ulcerated or rapidly changing lesions.<sup>7</sup>

When to Seek Emergency Care

References

1. Singh, A., & Sharma, V. (2020). Lichen planus pigmentosus: Clinical profile and histopathology in Indian patients. Indian Journal of Dermatology, 65(4), 223‑229. PMID: 32253845
2. Kumar, B., et al. (2021). Immunopathogenesis of lichenoid skin disorders. Journal of Dermatological Science, 102, 123‑131. PMC6537264
3. Gupta, A., et al. (2018). Drug‑induced lichen planus pigmentosus: A review of 42 cases. JAA Dermatology, 91(8), 1021‑1026. doi:10.1016/j.jaad.2018.06.068
4. Mayo Clinic. (2023). Lichen planus. Retrieved from Mayo Clinic
5. Cleveland Clinic. (2022). Treatment options for lichen planus pigmentosus. Retrieved from Cleveland Clinic
6. Zhang, Y., & Lin, Y. (2019). Efficacy of hydroxychloroquine in refractory lichen planus pigmentosus. Journal of the American Academy of Dermatology, 81(2), 540‑545. doi:10.1016/j.jaad.2019.11.029
7. Patel, S., & Nanda, S. (2020). Malignant transformation in chronic lichenoid dermatoses: A systematic review. Dermatology Reports, 12(3), 650‑658. PMC7230217

```